Sorrento Therapeutics (NASDAQ:SRNE) Coverage Initiated by Analysts at StockNews.com

by · The Markets Daily

StockNews.com began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Free Report) in a research report sent to investors on Sunday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Price Performance

Shares of Sorrento Therapeutics stock opened at $0.00 on Friday. Sorrento Therapeutics has a 12 month low of $0.00 and a 12 month high of $0.25. The business has a fifty day simple moving average of $0.01 and a 200 day simple moving average of $0.01.

Sorrento Therapeutics Company Profile

(Get Free Report)

Sorrento Therapeutics, Inc, a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.

See Also